VALYSTR · Stock research
Listed on NasdaqGS. What the market is pricing into Mesoblast Limited (MESO) in the Healthcare sector: implied growth, valuation scenarios, SEC-filed financials, and what has moved the stock.
Healthcare · Biological Products, (No Diagnostic Substances) · market value about $1.9B · revenue $120M (as of 2026-11-04)
Opening the full page… All companies · Research guides · What a reverse DCF shows